BiomX (PHGE) EBT (2018 - 2026)
BiomX (PHGE) posted EBT of -$19.1 million for Q1 2026, down 278.69% sequentially from $10.7 million in Q4 2025, and down 149.93% YoY from $38.3 million in Q1 2025.
BiomX (PHGE) EBT (2018 - 2026) Analysis & Trends
BiomX has reported EBT for 9 years, with the latest figure at -$19.1 million in Q1 2026.
- Quarterly EBT fell 149.93% year-over-year to -$19.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$23.6 million (down 279.33% YoY) and the FY2025 annual result came in at -$12.1 million, down 445.91% from the prior year.
- EBT fell to -$19.1 million in Q1 2026 per PHGE's latest filing, from $10.7 million in the prior quarter.
- Over five years, EBT peaked at $15.8 million in Q4 2022 and troughed at -$19.1 million in Q1 2026.
- A 5-year average of -$2.7 million and a median of -$6.4 million in 2023 frame the typical range for EBT.
- The sharpest annual moves came in 2022 and 2025: EBT jumped 251.45% in 2022, then sank 234.83% in 2025.
- Over 5 years, EBT stood at $15.8 million in 2022, then tumbled by 134.84% to -$5.5 million in 2023, then jumped by 222.31% to $6.7 million in 2024, then jumped by 59.51% to $10.7 million in 2025, then plunged by 278.69% to -$19.1 million in 2026.
- According to Business Quant data, EBT over the past three periods registered -$19.1 million, $10.7 million, and -$9.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 541.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -767.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 312.46 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 177.81 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -11.37 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -264.70 Mn |
| 10 | BiomX | 361,408.40 | -806,591.60 | - | -19.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.14 Mn |
| Dec 31, 2025 | 10.71 Mn |
| Sep 30, 2025 | -9.16 Mn |
| Jun 30, 2025 | -6.04 Mn |
| Mar 31, 2025 | -7.66 Mn |
| Dec 31, 2024 | 6.72 Mn |
| Sep 30, 2024 | 9.64 Mn |
| Jun 30, 2024 | 4.48 Mn |
| Dec 31, 2023 | -5.49 Mn |
| Sep 30, 2023 | -7.90 Mn |
| Jun 30, 2023 | -6.40 Mn |
| Mar 31, 2023 | -6.36 Mn |
| Dec 31, 2022 | 15.76 Mn |
| Sep 30, 2022 | -6.77 Mn |
| Jun 30, 2022 | -7.47 Mn |
| Mar 31, 2022 | -8.16 Mn |
| Dec 31, 2021 | -10.41 Mn |
| Sep 30, 2021 | -10.02 Mn |
| Jun 30, 2021 | -7.33 Mn |
| Mar 31, 2021 | -8.40 Mn |